CVKD NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Cadrenal Therapeutics, Inc. Common Stock · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 2.04 USD
-5.6% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -62.8% below the Trend Line and sits at 1.4% of its 52-week range. The latest completed week returned -5.6%, after a -33.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 51/100. Near-term considerations: earnings are due in 11d.

Setup score 16 out of 100
Latest Close 2.04 USD 24 Jul 2026
1W Return -5.6% latest completed week
4W Return -33.1% short-term follow-through
12W Return -67.9% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 1.0x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -5.6% Latest completed week; four-week move -33.1%. Indicator stack 0/35 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 41.51% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 51/100 61 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -62.8% below the Trend Line and sits at 1.4% of its 52-week range. The latest completed week returned -5.6%, after a -33.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0012-week average 0.03

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure5/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.00Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -33.1% over four weeks, -67.9% over 12 weeks, and -82.2% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-5.6%
4W-33.1%
12W-67.9%
26W-71.9%
52W-82.2%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.62Latest activity-pressure read.
Pressure change-47.4%Four-week change in activity pressure.
Leadership-77.77Latest relative-leadership reading.
RS change-9.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 64% Model confidence 61%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength70/100Blend of value, momentum, and quality. Underlying universe rank 31; rank 1 is best.
Value59/100Relative valuation strength. Underlying universe rank 42; rank 1 is best.
Quality58/100Profitability and accounting quality. Underlying universe rank 43; rank 1 is best.
Momentum59/100Medium-term price momentum. Underlying universe rank 42; rank 1 is best.
Growth59/100Revenue and earnings growth. Underlying universe rank 42; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-272.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-97.7%
Net share repurchases relative to market value.
Shareholder yield
-97.7%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment51/100

Weighted news tone is neutral across 61 relevant articles.

13 positive · 38 neutral · 10 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-86.1%Distance below the 52-week high.
13-week volatility12.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher8 of 2618 weeks finished lower.
Best week+24.0%Week of 27 Feb.
Worst week-25.3%Week of 17 Jul.
Latest week-5.6%Week of 24 Jul.

Shape of recent returns

Strong gains6
Modest gains2
Flat weeks0
Modest losses2
Sharp losses16
Recent vol12.3%13-week weekly-return volatility.
Base vol11.7%52-week weekly-return volatility.
Up/down split21/31Count of positive and negative weeks in the 52-week window.
Average skew8.2% / -9.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape17/100

Trend, activity pressure, participation, and risk combine to a 17/100 tape read.

 Indicator analysis26/100

Latest 12-week confirmation: trend 0/12, activity pressure 5/12, relative leadership 0/12.

Activity pressure 0.00; No reversal markers Next-Week ExpectancyNegative 41.51%

Next-week expectancy is negative with a 41.51% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors61/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 100 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment51/100

Weighted news tone is neutral across 61 relevant articles.

Cadrenal Therapeutics Inc (CVKD) Institutional Confidence Insiders50/100

No recent insider transaction evidence is stored.

 Earnings11d

Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20262.04 USD-5.6%5.48 USD10.69 USD-0.62-77.77378.6KOff
17 Jul 20262.16 USD-25.3%5.66 USD10.76 USD-0.53-77.40518.1KOff
10 Jul 20262.89 USD-19.7%5.83 USD10.86 USD-0.52-71.69271.7KOff
3 Jul 20263.60 USD18.0%6.10 USD10.97 USD-0.41-65.03637.8KOff
26 Jun 20263.05 USD-12.9%6.32 USD11.09 USD-0.42-70.83350.1KOff
19 Jun 20263.50 USD-5.4%6.53 USD11.22 USD-0.28-68.63347.9KOff
12 Jun 20263.70 USD-16.7%6.75 USD11.35 USD-0.02-66.75421.1KOff
5 Jun 20264.44 USD-10.5%7.02 USD11.47 USD0.16-60.24402.1KOff
29 May 20264.96 USD-4.4%7.27 USD11.60 USD0.35-58.70213.9KOff
22 May 20265.19 USD2.7%7.56 USD11.70 USD0.56-56.51290.5KOff
15 May 20265.05 USD-17.0%7.86 USD11.80 USD0.48-58.18280.2KOff
8 May 20266.09 USD-4.1%8.15 USD11.90 USD0.37-51.04371.1KOff
1 May 20266.35 USD15.5%8.40 USD12.00 USD0.07-47.37394.7KOff
24 Apr 20265.50 USD5.4%8.66 USD12.09 USD-0.22-54.89283.8KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.